Background-Many
A therosclerosis is a complex disease with many possible causes and many adverse clinical outcomes, including heart disease, myocardial infarction, stroke, embolism, thrombosis, and aneurysm. To date, many different genetic 1 and clinical 2 factors have been identified as causes or contributors to atherosclerosis. We present herein a model of preclinical atherosclerosis based on genetic and clinical data that predicts the presence of coronary artery calcification in healthy Americans of European descent 45 to 84 years of age.
Clinical Perspective on p 2454
There has been much progress in identifying genes and single-nucleotide polymorphisms (SNPs) associated with atherosclerosis 3 or clinical correlates of atherosclerosis (for example, contributing causes such as hypertension 4 and consequences such as myocardial infarction 5 ). There have also been successful predictive models of the effects of atherosclerosis, including heart disease 6 and thromboembolism, 7 and these particular models were successful without the inclusion of genetic information. Additionally, 1 study considered 30 possible genetic markers 8 in a predictive model of atherosclerosis but concluded that the few SNPs available were unhelpful in predicting atherosclerosis. It appears clear that to achieve a more complete model of atherosclerosis, a multitude of genes and clinical variables must be combined. 9 The Multi-Ethnic Study of Atherosclerosis (MESA) recruited a cohort of individuals without clinical evidence of cardiovascular disease (CVD) and then measured coronary artery calcification (CAC), a quantifiable marker of advanced atherosclerosis. 10 A large number of candidate genes, 231, related to vascular disease and related phenotypes were selected for genotyping, and extensive clinical and demographic data were collected on the subjects. With these combined data, MESA provides an ideal opportunity to investigate both clinical and genetic models of CAC as an indicator of atherosclerosis.
Methods
MESA is a population-based study of 6814 men and women 45 to 84 years of age who were free of known CVD at baseline and who were recruited between 2000 and 2002 from 6 US communities. The main objective of MESA is to determine the characteristics of subclinical CVD and its progression. Details of the objectives and design of MESA have been published previously. 10 Institutional review board approval was obtained at all MESA sites, and all participants gave their informed consent.
For initial genotyping analyses, a subcohort of 720 subjects was selected from the total MESA cohort of 6814; these participants both gave informed consent for DNA extraction and the genetic substudy and had samples in the study DNA laboratory with sufficient DNA. All DNA was of high quality as measured by OD260/OD280, with a mean ratio of 1.77. All DNA was of high molecular weight as determined by gel electrophoresis. For the present study, to minimize the possibility of spurious genetic associations due to population stratification, we analyzed the data from the MESA participants who were self-identified as having European ancestry. Priority was given to subjects who participated in the MESA 3 additional blood biomarker collection, supplemented by random selection from remaining participant samples to fulfill balanced ethnic group representation and equality by gender. CAC was determined with electron-beam or helical computed tomography. 11 The average Agatston score of 2 scans was used, and the presence of CAC was defined as an Agatston score Ͼ0.
DNA was extracted from peripheral leukocytes isolated from packed cells of anticoagulated blood by use of a commercially available DNA isolation kit (Puregene; Gentra Systems, Minneapolis, Minn). The DNA was quantified by determination of absorbance at 260 nm followed by PicoGreen analysis (Molecular Probes, Inc, Eugene, Ore). Two vials of DNA were stored per participant at Ϫ70°C and subsequently separated into aliquots for use.
MESA investigators proposed candidate genes for 2 separate genemarker panels (MESA candidate gene panels 1 and 2), and the genes were priority ranked by contributing investigators. The list of genes included is shown in Table I in the online-only Data Supplement. For panel 2, additional weight was given to genes proposed by the MESA Eye ancillary study, a study of retinal microvascular characteristics as predictors of subclinical and clinical CVDs. Final priority for both panels was assigned by the MESA Family Study Genetics Committee. SNPs for the chosen genes were selected according to the following criteria:. First, SNPs within the proximal and distal 10-kb regions 5Ј and 3Ј to the given candidate gene (National Center for Biotechnology Information Build 35) were chosen. Next, SNP compatibility with the Illumina GoldenGate technology 12,13 as determined by the Assay Design Tool (TechSupport, Illumina, San Diego, Calif) was required. Finally, SNPs were selected that had minor allele frequency Ն0.05 or a tag (r 2 Ն0.8) for another SNP with minor allele frequency Ͼ0.05 as determined by application of the multilocus or "aggressive" Tagger option of Haploview version 3 14, 15 with International HapMap project data for CEPH (Centre d'Etude du Polymorphisme Humain) and Yoruban populations (release 19). 16 Because of these competing criteria, a complete set of tag SNPs could not be found for some genes, and additional SNPs were selected from 1 of the following 3 sources: (1) ldSelect analysis of resequencing information from the SeattleSNPs project if available 17, 18 ; (2) nonsynonymous SNPs from dbSNP (release 124) 19 ; and (3) SNPs with a prior report of an association with a phenotype similar or identical to one measured in MESA and proposed by a MESA investigator.
In MESA candidate gene panel 1, ancestry informative markers were selected from an Illumina proprietary SNP database to maximize the difference in allele frequencies between any pair of ethnic groups: Caucasian-versus African-American, Caucasian-versus Chinese-American, and African-versus Chinese-American. For MESA candidate gene panel 2, additional markers informative for Mexican-American ancestry were selected from published lists. 20, 21 Genotyping was performed by Illumina Genotyping Services with their proprietary GoldenGate assay. The SNPs were typed in 2 separate panels of 1536 markers, selected to assay multiple phenotype-by-gene hypotheses. Illumina performed initial quality control in their laboratory to identify samples and SNPs that failed genotyping according to proprietary protocols, as well as sporadic failed genotypes with a GenCall quality score Ͻ0.25. Of 156 duplicate pairs included in 33 plates of samples typed, Illumina was blinded to 92 pairs. Both unblinded and blinded sample replicate concordance rates were Ͼ99.99%. After removal of failed SNPs and samples, the genotype calling rate was 99.93%, with a maximum missing data rate per sample of 2.1%, and maximum missing data per SNP of 4.98%. The cohort genetic data were checked for cryptic sample duplicates and discrepancies in genetically predicted sex (with X markers) versus study database-reported sex. Samples with unresolved duplicate and sex discrepancies were removed from the genetic study database.
These criteria resulted in 712 individuals of European descent genotyped at 2882 SNPs. A total of 393 members (55.2%) of the cohort were previously determined to have detectable CAC at the baseline examination. Missing SNP values in the genotype data were imputed by random assignment according to the marginal frequencies of each SNP across the cohort, in an effort to favor the null hypothesis of no association as much as possible. Five hundred ninety-three of the SNPs were removed for having minor allele frequencies Ͻ5%. A further 111 autosomal SNPs were rejected because the distribution of their alleles violated Hardy-Weinberg equilibrium (PϽ0.05). 22 These tests resulted in a total of 2177 SNPs being eligible for our model search algorithms.
Additional nongenetic data were available for each individual, and we selected the following for inclusion in our model-building process on the basis of suspected associations with atherosclerosis or CVD: Age, sex, education level, income, smoking status, weight, body mass index, diabetes mellitus, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, total cholesterol, systolic blood pressure, diastolic blood pressure, hypertension, walking speed, and minutes of exercise per week. Income and education were included as potential proxies for other unmeasured environmental factors. In all categories, responses were binned into no more than 5 discrete values by use of a simple linear binning strategy (different binning strategies did not affect results).
We then sorted all remaining variables by their Bayes factor, 23 a statistic that assesses the likelihood increase associated with conditioning the outcome (presence of CAC) on the variable in question. A Bayes factor Ͼ1 (or equivalently, the log of the Bayes factor Ͼ0) for a particular variable indicates that the variable in question is more likely to be probabilistically associated with coronary calcification than to be probabilistically independent of it. Bayes factors were computed with conjugate Dirichlet priors as described by Cooper and Herskovitz. 24 We used the Bayes factors to filter the number of SNPs to a tractable amount: Only 50 SNPs had a log Bayes factor Ͼ0, and the 17 SNPs with the highest Bayes factors were all on the X chromosome. We also noted that 10 of the clinical variables had a log Bayes factor Ͼ0 (age, sex, diabetes, systolic blood pressure, hypertension, HDL cholesterol, smoking, body mass index, total cholesterol, and education). All SNPs and clinical variables with a log Bayes factor Ͼ0 are listed in Table II in the online-only Data Supplement. We used Bayesware Discoverer (www.bayesware.com) to create a Bayesian network structure based on these variables. A Bayesian network is a statistical method with properties that ideally suit it to the task of discovering predictive models of complex diseases. 25, 26 Among these is the ability of the model marginal likelihood to penalize model complexity without need of further adjustment. 27 Indeed, Bayesian networks have proved successful in previous prediction problems of complex diseases, including stroke. 28 We built 3 separate Bayesian network models, one that used the 50 positive-Bayes-factor SNPs alone, another that used all 16 clinical variables alone, and a third that used the combination of the 50 SNPs and 16 clinical variables.
We compared the performance of the 3 different models using the area under the convex hull of the receiver operating characteristic curve (AUC), which measures performance of a classifier at different false-positive/false-negative thresholds. We then followed the prescription of Lasko et al 29 to compute a P value comparing the difference of 2 AUCs, computing the variance of an AUC according to the nonparametric method described by DeLong et al. 30 Results Table 1 shows demographic data for the study participants. We developed a Bayesian network using all available data; the Markov blanket of CAC in the network is depicted in Figure 1 . It uses all the variables listed in Table 2 except for SNP rs2380316 on the X chromosome (variable number 18 in Table 2 ): 5 Clinical variables and 13 SNPs. This model has an 85% AUC in the entire European MESA cohort for predicting the presence of CAC (Figure 2) . For comparison purposes, we then obtained a Bayesian network using only the genomic data, and the 14 SNPs used in this network are shown in Table 2 (numbers 6 to 17 and 19). The model consisted of 14 SNPs directly related to the phenotype (CAC); there were no other connections. This model differed from the first by the inclusion of an extra SNP on the X chromosome, rs2380316, which may act as a proxy for the absent sex attribute. This model achieved 77% AUC ( Figure 2 ). The performance of the combined SNP-clinical model was significantly better than the SNP-only model (PϽ0.001) by the method of DeLong et al. 30 We then compared our results against a Bayesian network constructed from only the clinical data. This model included the following features: Sex, age, diabetes, smoking, and weight ( Figure 3 ). Other attributes did not impact the presence of CAC according to the model. Nevertheless, this model achieved comparable accuracy to the SNP-only model (78.3% AUC; Figure 3 ). These models were tested for statistical difference from the results of the combined SNPclinical model and found to be significant (PϽ0.001 by the method of DeLong et al 30 ) , although these results were not significantly different from the performance of the SNP-only model. These observations are summarized in Table 3 .
Finally, we attempted to construct models using logistic regression with stepwise selection of the same types as our Bayesian networks. A logistic regression model constructed from the 50 SNPs and 16 clinical attributes achieved 81.5% AUC (Pϭ0.036 versus 85% AUC of our Bayesian model), with the attributes of age, sex, diabetes mellitus, smoking, total cholesterol, and 6 SNPs (numbers 11 and 16 in Table 2 , an X-linked SNP rs953114, and 3 SNPs on genes included in the Bayesian model: rs1403543 on AGTR2, rs2498852 at FBLN5, and rs6502804 in ALOX15.) A logistic regression model that used only clinical variables performed less well, with an AUC of 78.9% (not significantly different from the Bayesian clinical-only model, Pϭ0.256), but other researchers have previously obtained a logistic model for the entire European MESA cohort (nϭ2619) with an AUC of 82%. 2 Logistic regression limited to SNPs had a predictive accuracy of 66.6% AUC and was significantly worse (PϽ1.77ϫ10 Ϫ7 ) than the Bayesian SNP-only model (this regression model contained 8 SNPs: 2 X-linked; 2 from the combined logistic model, rs2498852 at FBLN5 and rs6502804 on ALOX15; and 4 listed in Table 2 , numbers 8, 11, 16, and 17).
Discussion
The results of the present study show that it is possible to combine genetic data with clinical data and achieve improvements in predictive accuracy. The performance of the combined model (85% AUC) was comparable to or better than existing predictors of atherosclerosis. Previous studies either have investigated related but different phenotypes (eg, myocardial infarction, thrombosis) or have had different phenotyping criteria (work by Chen et al 8 checked for a 50% narrowing of any coronary artery, a separate indicator of atherosclerosis, in which narrowing of an artery can be due to uncalcified plaques).
We note that multiattribute methods are required to achieve a well-performing predictive model of atherosclerosis. We tested each individual attribute involved as a single predictor of CAC (summarized in Table 2 ). Individual attributes were poor predictors of CAC, except for sex and age; other attributes only achieved AUCs in the range of 53% to 59%. Table 2 also lists P values for the difference between the performance of a single attribute predictor and a random classifier, and 10 of these were significant at a 0.05 threshold.
The network depicted in Figure 1 shows that 13 SNPs, located on 12 genes and 1 ancestry informative marker, modulated the risk of CAC. Note that although ancestry informative markers were included in the genotyping for purposes related to other investigations, it nevertheless turned out that an ancestry informative marker was included in the model.
Because the SNPs genotyped in the MESA study were chosen as tag SNPs, and these were chosen for their candidacy in relation to previous knowledge about the genetics of atherosclerosis and CVD, these 12 SNPs represented various connections and relations to atherosclerosis and related physiology. Four of these 12 genes fell into a coherent functional picture related to lipid metabolism, centered on the adipocytokine signaling pathway (PRKAB1, 31 AMPK, 31 PPARA, 32 and AMPK, along with INSR, which is also related to the insulin signaling pathway 33 ), whereas the fourth was related to high-density lipoprotein-and low-density lipoproteinbound cholesterols (PON1. 34 ) Five genes represented in our model could be broadly grouped by their relation to vascular inflammation or constriction (AGTR1, 35 VEGFA 36 ) or general inflammation responses (ALOX15, 37 IL1R2, 38 and PLA2G7 39 ). Several genes have previously been associated with atherosclerosis (PON1, 40 ALOX15, 41 and FBLN5 and ESR2 [42] [43] [44] ). The twelfth gene (KCNK1), a ubiquitous potassium ion channel, has been linked to heart cells but not vasoconstriction, with differential expression in ventricular and atrial cells. 45 Our work here should be considered in light of its scope and limits. First, because the total predictive accuracy was imperfect, we speculate that further genetic investigations will uncover better models. Genome-wide association studies of atherosclerosis, measuring hundreds of thousands of SNPs rather than just thousands, could uncover unknown dependencies between genes in our model, or entirely new genes. It also may be possible that there are further clinical attributes beyond those collected in MESA or used in the present model that may be of relevance to the prediction of CAC. Second, the present work is limited to the European cohort of the MESA study, although studies on other ethnic groups are in preparation. Because we used the MESA data, our prediction was for the presence or absence of CAC, which is only 1 measure of atherosclerosis. It may be easier to predict atherosclerosis or the onset of CVD when different clinical phenotypes are used, or even different CAC thresholds; a CAC raw Agatston score Ͼ400, for example, is frequently considered an indicator of increased CVD risk, 46 one we did not consider because the number of MESA patients who met this threshold was low (nϭ83). Furthermore, because atherosclerosis affects such a large proportion of the population, and risk is largely dependent on age and sex, it may be more informative to predict who will develop atherosclerosis earlier or later than expected after more data are available for the onset of atherosclerosis. Last but not least, the models in the present study have not been tested on an external replication population. Thus, modifications to our model may be necessary to achieve robust prediction in different populations, from other studies or other demographic groups. For each model, we report the AUC. The performance of the SNP-Clinical model was found to be a statistically significant improvement over the use of either category of information separately.
